Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Inhibikase Therapeutics Logo
Inhibikase Therapeutics Growth Score
71
CB Rank
128823
Heat Score
46
Inhibikase Therapeutics is a developer of cellular Abelson tyrosine kinase inhibitors to treat infections and other diseases.
Founded
obfuscation
PublicPost-IPO Equity Atlanta, Georgia, United States11-50 www.inhibikase.com/
Health Care
Health Diagnostics
Therapeutics
Overview

Inhibikase Therapeutics
Total Funding
obfuscation
Growth Score
71
Heat Score
46

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score71
-9 pts
in past quarter
Heat Score 46
-12 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Inhibikase Therapeutics

CB Rank
128823
Inhibikase Therapeutics is a developer of cellular Abelson tyrosine kinase inhibitors to treat infections and other diseases.
Founded
obfuscation
PublicPost-IPO Equity Atlanta, Georgia, United States11-50 www.inhibikase.com/
Health Care
Health Diagnostics
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Inhibikase Therapeutics, Inc.
Operating Status Active
Stock Symbol  NASDAQ:IKT
Company Type For Profit
Founders  Milton Werner
About the Company
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.
Phone Number 617-936-0184
Predictions & Insights

Growth Insight

See this Growth Insight
Inhibikase Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Risvodetinib (IkT-148009)
An oral small-molecule c-Abl kinase inhibitor designed to halt and reverse dopamine neuron loss in Parkinson’s disease and related disorders.
IkT-001Pro (Prodrug of Imatinib Mesylate)
An optimized prodrug formulation of imatinib mesylate developed for treating pulmonary arterial hypertension (PAH) and chronic myelogenous leukemia (CML).

Research & Development

Inhibikase Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 12
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 12
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Inhibikase Therapeutics Logo
Post-IPO Equity - Inhibikase Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 4 Board Members and Advisors 6 Contacts 8

Employee Profiles

Board Members and Advisors

News

News and Press

News•Apr 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 23, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,454
-71.15%
 in past month

IT Spend

$435.5KThis year, Inhibikase Therapeutics is projected to spend $435.5K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Sony (SNE) Logo
Sony (SNE)
91
Projector Logo
Projector
84
Connected Cars Logo
Connected Cars
79

Active Website Tech Count

22Inhibikase Therapeutics is actively using 22 technologies for its website, according to BuiltWith. These include HSTS, Apple Mobile Web Clips Icon, and  Euro.

Total IP

22The intellectual property of Inhibikase Therapeutics includes 17 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Inhibikase Therapeutics has registered 5 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Inhibikase Therapeutics's headquarters? Inhibikase Therapeutics is located in Atlanta, Georgia, United States.Who invested in Inhibikase Therapeutics? Inhibikase Therapeutics has 14 investors including Blackstone Group and  Spruce Street Capital.When was the last funding round for Inhibikase Therapeutics? Inhibikase Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Inhibikase Therapeutics's competitors? Alternatives and possible competitors to Inhibikase Therapeutics may include Cerevance, Alumis, and  Roivant Sciences.How much funding has Inhibikase Therapeutics raised to date? Inhibikase Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3237dbc 1)
|